Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sales milestone income of $50 million, according to a Thursday filing with the Australian bourse.

The company's royalties from partner Acadia Pharmaceuticals increased to AU$13.2 million in the third quarter, bringing the cumulative royalties for the year to AU$37.5 million, the filing said.

The company estimates fourth quarter royalties to be between AU$16 million and AU$18 million.

Additionally, the company anticipates a total income of AU$216 million to AU$218 million for 2024, including royalties, sales milestone payment, the share of the Rare Pediatric Disease Priority Review Voucher proceeds from Acadia Pharmaceuticals' sale, and AU$11m in interest income, according to the filing.

Neuren Pharmaceuticals shares rose nearly 7% in afternoon trade.